Summary:
- Aqtual, a precision medicine company in Hayward, CA, raised $31M in Series B funding.
- The funding came from investors like Bold Capital, Genoa Ventures, and others.
- Aqtual plans to use the funds to expand operations and research and develop new products for chronic disease management and oncology.
Rewritten Article:
Aqtual Raises $31M in Series B Funding
Aqtual, a precision medicine company based in Hayward, CA, recently secured $31 million in Series B funding to support its innovative active chromatin cell-free DNA (cfDNA) platform. The investment round saw participation from prominent investors including Bold Capital, Genoa Ventures, Manta Ray Ventures, and Yu Galaxy.
The company’s focus lies in developing cutting-edge products for chronic disease management and oncology using a unique cell-free DNA-based platform. This platform allows for the evaluation of protein regulation, epigenetics, and transcriptomics solely through cell-free DNA fragments present in the bloodstream. By leveraging this technology, Aqtual enables real-time analysis of disease progression and treatment efficacy, addressing the limitations of previous cell-free DNA methodologies.
One of Aqtual’s key strengths lies in its proprietary approach that facilitates high-fidelity quantification of tissue-specific gene regulation directly from blood samples. This integrated profiling technique offers insights into disease mechanisms, microenvironment factors, and the systemic immune response, enhancing the understanding of complex diseases.
With the newly acquired funds, Aqtual aims to expand its operations and intensify its research and development efforts to bring forth innovative solutions for precision medicine. The company’s commitment to advancing healthcare through technology-driven approaches positions it as a key player in the evolving landscape of personalized medicine.
Stay tuned for more updates on Aqtual’s groundbreaking advancements in the field of precision medicine.
